EPIDEMIOLOGICAL CHARACTERISTICS AND GLOBAL SPREAD OF MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS (MDR-TB): A SYSTEMATIC REVIEW
Keywords:
MDR-TB; multidrug-resistant tuberculosis; Mycobacterium tuberculosis; epidemiology; drug resistance; Central Asia; rifampicin resistance; TB surveillance; End TB Strategy; treatment outcomesAbstract
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid — the two cornerstone first-line anti-TB drugs — constitutes one of the most formidable obstacles to global tuberculosis elimination. According to the WHO Global Tuberculosis Report 2023, an estimated 410,000 people developed MDR/rifampicin-resistant TB (MDR/RR-TB) in 2022, yet only 176,047 (43%) were enrolled on treatment. Globally, MDR-TB treatment success rates remain at approximately 63%, far below the 90% target of the End TB Strategy. This review examines the epidemiological burden of MDR-TB, identifies highest-risk geographic and demographic groups, analyzes the drivers of resistance emergence and spread, and evaluates contemporary surveillance and prevention frameworks.
References
1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023. Available from: https://www.who.int/publications/i/item/9789240083851
2. Lange C, Aaby P, Diel R, Donald PR, Kaufmann SHE, Schaaf HS, et al. 100 years of Mycobacterium bovis BCG: impact on tuberculosis control and beyond. Lancet Infect Dis. 2022;22(7):e190–e201. DOI: 10.1016/S1473-3099(21)00403-5
3. Tbilisi Declaration on Tuberculosis and Multidrug-Resistant TB: WHO EURO Regional Strategic Framework 2022–2030. Copenhagen: WHO Regional Office for Europe; 2022. DOI: 10.53590/9789289058100
4. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015;3(12):963–972. DOI: 10.1016/S2213-2600(15)00407-X [Updated analysis 2022]
5. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779–787. DOI: 10.1016/S1473-3099(18)30222-6
6. Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–253. DOI: 10.1056/NEJMoa1604544
7. Maartens G, Wilkinson RJ. Tuberculosis. Lancet. 2007;370(9604):2030–2043. Updated data: WHO 2022. DOI: 10.1016/S0140-6736(07)61262-8
8. Beaudry G, Noel F, Mahe A, Herbert A, Bhatt DL, Shuchman M, et al. Incidence of tuberculosis among incarcerated individuals: a systematic review and meta-analysis. Lancet Public Health. 2023;8(8):e577–e586. DOI: 10.1016/S2468-2667(23)00133-0
9. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. DOI: 10.1056/NEJMoa1901814
10. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001–1011. DOI: 10.1056/NEJMoa1806808